Last reviewed · How we verify
NCT00076960
Compassionate Use of Stanate (TM) [Stannsoporfin]
trial testing Stanate (TM) [stannsoporfin, tin-mesoporphyrin] in Neonatal Jaundice. No longer available.
Quick facts
| Lead sponsor | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stanate (TM) [stannsoporfin, tin-mesoporphyrin] — full drug profile →
Conditions studied
- Neonatal Jaundice — all drugs for Neonatal Jaundice →
- Hyperbilirubinemia — all drugs for Hyperbilirubinemia →
Sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company — full company profile →
Who can join
Adults 12 Hours to 1 Week, any sex, with Neonatal Jaundice or Hyperbilirubinemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to make Stanate (TM) \[stannsoporfin, tin-mesoporphyrin\] available to infants who meet the following criteria: 1. the infant has a very high level of bilirubin without an adequate clinical response to phototherapy; 2. the infant requires an exchange transfusion; and 3. the family refuses to allow the administration of blood products, particularly on religious grounds, such as within the Jehovah's Witness community.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00076960
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neonatal Jaundice
Currently open trials in the same condition.
- NCT06963450 — NeoSCB App for Screening Jaundice in Newborns · recruiting
- NCT06399146 — Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana · NA · recruiting
- NCT05521607 — Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago) · NA · recruiting
Other InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company trials
Trials by the same sponsor.
- NCT02000830 — Follow up Study of Patients Having Participated in Clinical Trial 64,185-204 · completed
- NCT01887327 — Stannsoporfin With Light Therapy for Newborn Babies With Jaundice · Phase 2 · completed
- NCT02033096 — Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00076960 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
- Last refreshed: 15 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00076960.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing